Kura Oncology, Inc. $KURA Shares Bought by Algert Global LLC

Key Points

• Algert Global LLC increased its holdings in Kura Oncology by 8.5%, acquiring an additional 74,789 shares to reach a total of 958,492 shares worth approximately $6.3 million.
• Several large investors, including Fox Run Management and Invesco Ltd., have made significant investments in Kura Oncology, indicating growing interest in the company.
• Kura Oncology's stock has a current average price target of $24.10, with the consensus rating classified as a "Moderate Buy."

Algert Global LLC lifted its holdings in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 8.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 958,492 shares of the company's stock after acquiring an additional 74,789 shares during the period. Algert Global LLC owned approximately 1.11% of Kura Oncology worth $6,326,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Fox Run Management L.L.C. acquired a new stake in shares of Kura Oncology in the first quarter worth $158,000. E Fund Management Co. Ltd. increased its position in shares of Kura Oncology by 18.9% in the first quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company's stock worth $81,000 after acquiring an additional 1,951 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Kura Oncology by 13.5% in the first quarter. Russell Investments Group Ltd. now owns 338,859 shares of the company's stock worth $2,236,000 after acquiring an additional 40,197 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Kura Oncology in the first quarter worth $1,564,000. Finally, Invesco Ltd. increased its position in shares of Kura Oncology by 44.6% in the first quarter. Invesco Ltd. now owns 97,216 shares of the company's stock worth $642,000 after acquiring an additional 29,978 shares in the last quarter.

Wall Street Analyst Weigh In

KURA has been the subject of several recent research reports. Wall Street Zen raised shares of Kura Oncology from a "sell" rating to a "hold" rating in a research report on Sunday. Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a research note on Friday, June 20th. Mizuho dropped their price target on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, May 19th. JMP Securities dropped their price target on shares of Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating on the stock in a research note on Monday, August 11th. Finally, Barclays dropped their price target on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Kura Oncology has a consensus rating of "Moderate Buy" and an average price target of $24.10.

Kura Oncology Price Performance

Shares of KURA stock opened at $7.34 on Monday. The firm has a market cap of $637.11 million, a P/E ratio of -3.25 and a beta of 0.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.16 and a quick ratio of 6.16. Kura Oncology, Inc. has a 1-year low of $5.41 and a 1-year high of $21.57. The firm has a fifty day moving average of $6.20 and a two-hundred day moving average of $6.63.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.90). The business had revenue of $15.29 million for the quarter, compared to the consensus estimate of $64.95 million. As a group, research analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.